| Autor: |
Anagnostou A; Department of Pediatrics, Section of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Houston, Tex., Upton JEM; Department of Paediatrics, Division of Immunology and Allergy, The Hospital for Sick Children, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Chinthrajah RS; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif. Electronic address: schinths@stanford.edu. |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Jan; Vol. 153 (1), pp. 95-97. Date of Electronic Publication: 2023 Nov 20. |
| DOI: |
10.1016/j.jaci.2023.11.009 |
| Abstrakt: |
Competing Interests: Disclosure Statement Disclosure of potential conflict of interest: A. Anagnostou reports receiving institutional funding from Aimmune and Novartis; serving as an advisory board member at Novartis and Ready, Set, Food; and receiving consultation and/or speaker fees from ALK, Adelphi, EPG Health, Aimmune Therapeutics, and Genentech. J. E. M. Upton reports receiving research support and/or grants from Novartis, Regeneron, ALK Abelló, DBV Technologies, CIHR, and the SickKids Food Allergy and Anaphylaxis Program; receiving fees from Pfizer, ALK Abello, Bausch Health, and Astra Zeneca; serving as an associate editor for Allergy Asthma and Clinical Immunology; and serving on the board of directors of the Canadian Society of Allergy and Clinical Immunology and the Healthcare Advisory Board of Food Allergy Canada, all outside the submitted work. R. S. Chinthrajah reports receiving grant support from the Consortium for Food Allergy Research, the National Institute of Allergy and Infectious Disease, Food Allergy Research and Education and serving as an advisory board member for Alladapt Immunotherapeutics, Novartis, Allergenis, Intrommune Therapeutics, Phylaxis, and Genentech. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect